載入...

Riociguat for pulmonary arterial hypertension associated with congenital heart disease

OBJECTIVE: The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explor...

全面介紹

Na minha lista:
書目詳細資料
發表在:Heart
Main Authors: Rosenkranz, Stephan, Ghofrani, Hossein-Ardeschir, Beghetti, Maurice, Ivy, Dunbar, Frey, Reiner, Fritsch, Arno, Weimann, Gerrit, Saleh, Soundos, Apitz, Christian
格式: Artigo
語言:Inglês
出版: BMJ Publishing Group 2015
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4680166/
https://ncbi.nlm.nih.gov/pubmed/26135803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/heartjnl-2015-307832
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!